Assessment of quality of life in patients with chronic hepatitis C combined with non-alcoholic fatty liver disease and obesity after comprehensive therapy
DOI:
https://doi.org/10.32782/2077-6594/2025.2/02Keywords:
HCV, NAFLD, combined therapy, quality of life, questionnaireAbstract
The aim of this study was to assess the effectiveness of combined therapy using ademetionine and ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C (CHC), non-alcoholic fatty liver disease (NAFLD), and obesity. The main objective was to evaluate how this treatment regimen affects clinical indicators, liver function, and overall quality of life, particularly physical and psychological well-being.Materials and methods. A prospective study involved 70 patients with verified CHC diagnosis, NAFLD and obesity. The average age of patients was 58.5 ± 1.5 years. A control group (n = 25, average age 33.2 ± 1.5 years) consisted of healthy individuals.The participants were divided into three groups. The first group received standard antiviral therapy. The second group received antiviral therapy plus ademetionine, and the third group received a combination of ademetionine and UDCA along with antiviral therapy. Quality of life was assessed using SF-36 and EQ-5D questionnaires at the beginning of treatment, and after three and six months of therapy.Results. Patients receiving the combined treatment with ademetionine and UDCA showed the most significant improvements in quality of life, particularly in physical function, pain reduction, and mental health. They reported decreased anxiety and depression and improved social activity. Those receiving antiviral therapy with ademetionine also showed improvement, but to a lesser degree.No significant changes were observed in the control group.Conclusion. Combined therapy with ademetionine and UDCA alongside antiviral treatment is an effective approach for patients with CHC, NAFLD, and obesity, improving both clinical outcomes and quality of life, particularly in physical and psychological domains.
References
Suda G, Sakamoto N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J Gastroenterol Hepatol. 2021;36(5):1152-1158. DOI: 10.1111/jgh.15189.
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017 Jan;152(1):142–156. DOI: 10.1053/j.gastro.2016.09.009.
Tachi Y, Hirai T, Miyata A. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res. 2015;45(2):238-46. DOI: 10.1111/hepr.12331.
She Y, Mangat R, Tsai S, Proctor SD, Richard C. The Interplay of Obesity, Dyslipidemia and Immune Dysfunction: A Brief Overview on Pathophysiology, Animal Models, and Nutritional Modulation. Front Nutr. 2022 Feb 17;9:840209. DOI: 10.3389/fnut.2022.840209.
Wu P, Zhao J, Guo Y, Yu Y, Wu X, Xiao H. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun. 2020;529(3):834–8. DOI: 10.1016/j.bbrc.2020.05.128.
Wang L, Guo J, Lu J. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget. 2016;7(24):35632. DOI: 10.18632/oncotarget.9691.
Roudot-Thoraval F. Epidemiology of hepatitis C virus infection Clinics and Research in Hepatology and Gastroenterology. 2021;45:101596. DOI: 10.1016/j.clinre.2020.101596.
Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva K, Pirogova I, Chesnokov E, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959. DOI: 10.3748/wjg.v27.i10.959.
Cruz BL da, Simioni PU, Carmo TA do. Life quality among consumers of psychoactive substances: evaluation of the Medical Outcomes Study Short Form 36. SMAD Rev eletrônica saúde Ment álcool e Drog. 2019;15(3):1–9. DOI: https://doi.org/10.11606/ issn.1806-6976.smad.2019.000422.
Adriaan J. van der Meer, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014 Nov 12;312(18):1927–8. DOI: 10.1001/jama.2014.12627.
Ji D, Chen G-F, Niu X-X et al. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Elsevier. Metabolism Open. 2021;10:10090. DOI: 10.1016/j.metop.2021.100090.
Meissner EG, Lee Y-J, Osinusi A. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015; 61:790–801. DOI: 10.1002/hep.27424.
Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425–443. DOI: 10.1016/j.jhep.2016.04.005.
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017 Jun 6;2017(6):CD012143. DOI: 10.1002/14651858.
Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review. Front Public Heal. 2021;9:6755-63. DOI: https://doi.org/10.3389/fpubh.2021.675523.
Gheibi S, Ghaleh HEG, Motlagh BM, Azarbayjani AF, others. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. Biomed Pharmacother. 2019;115:108938. DOI: 10.1016/j.biopha.2019.108938.
Hadefi A, Arvanitakis M, Trépo E, Zelber-Sagi S. Dietary strategies in non-alcoholic fatty liver disease patients: From evidence to daily clinical practice, a systematic review. United European Gastroenterol J. 2023;11(7):663-689. DOI: 10.1002/ueg2.12443.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362 (18):1675-85. DOI: 10.1056/NEJMoa0907929.
McGregor G, Powell R, Kimani P, Underwood M. Does contemporary exercise-based cardiac rehabilitation improve quality of life for people with coronary artery disease? A systematic review and meta-analysis. BMJ Open. 2020;10(6):1-19. https://doi.org/10.1136/bmjopen-2019-036089.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo- controlled trial. The Lancet. 2015 Mar 14;385(9972):956-965. doi: 10.1016/S0140-6736(14)61933-4.
